Table 2 Baseline demographic and clinical characteristics of patients
Primary cohort (n = 31) | Validation cohort (n = 15) | p value (Inter cohorts) | |||
|---|---|---|---|---|---|
Non-response group (n = 16) | Response group (n = 15) | p value | |||
Age (years)a | 64.25 ± 8.00 | 61.47 ± 8.63 | 0.259 | 63.40 ± 7.52 | 0.805 |
Sex | 1.000 | 1.000 | |||
Male | 8 (50.0%) | 8 (53.3%) | 7 (46.7%) | ||
Female | 8 (50.0%) | 7 (46.7%) | 8 (53.3%) | ||
CEA (ng/mL)b | 3.15 (2.55–5.73) | 2.00 (1.60–2.80) | 0.028 | 2.90 (2.30–4.70) | 0.489 |
CA19-9 (U/mL)b | 328.40 (120.78–469.38) | 75.00 (45.80–166.30) | 0.022 | 164.80 (22.70–429.50) | 0.648 |
Tumour location | 0.032 | 1.000 | |||
Pancreatic head | 11 (68.8%) | 4 (26.7%) | 8 (53.3%) | ||
Pancreatic neck, body, and tail | 5 (31.3%) | 11 (73.3%) | 7 (46.7%) | ||
Grade of tumour | 1.000 | 1.000 | |||
2 | 5 (31.3%) | 5 (33.3%) | 5 (33.3%) | ||
3 | 11 (68.8%) | 10 (66.7%) | 10 (66.7%) | ||
Stage of tumour | 0.585 | 0.848 | |||
I | 6 (37.5%) | 8 (53.3%) | 6 (40.0%) | ||
II | 7 (43.8%) | 4 (26.7%) | 5 (33.3%) | ||
III | 3 (18.8%) | 3 (20.0%) | 4 (26.7%) | ||
Median DFS (months) | 6.0 | 23.7 | < 0.001 | 11.0 | 0.772 |